Evidence map›Paper›PMID 29990545›Full record

ArticleThe ocular surface2018

PPARγ regulates meibocyte differentiation and lipid synthesis of cultured human meibomian gland epithelial cells (hMGEC).

Sun Woong Kim, Yilu Xie, Paul Q Nguyen, Vickie T Bui, Kelly Huynh, Jonathan S Kang, Donald J Brown, James V Jester

Open access · greenAbstract read
In one paragraph

Article in The ocular surface, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
5.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 64 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Photothermal-Responsive Soluble Microneedle Patches for Meibomian Gland Dysfunction Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Isolation and Culture of Human Meibomian Gland Ductal Cells.Investigative ophthalmology & visual science · 2023
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Sun Woong KimGavin Herbert Eye Institute, University of California Irvine, Irvine, CA, United States; Department of Ophthalmology, Yonsei University Wonju College of Medicine, Wonju, South Korea.
Yilu XieGavin Herbert Eye Institute, University of California Irvine, Irvine, CA, United States.
Paul Q NguyenGavin Herbert Eye Institute, University of California Irvine, Irvine, CA, United States.
Vickie T BuiGavin Herbert Eye Institute, University of California Irvine, Irvine, CA, United States.
Kelly HuynhGavin Herbert Eye Institute, University of California Irvine, Irvine, CA, United States.
Jonathan S KangGavin Herbert Eye Institute, University of California Irvine, Irvine, CA, United States.
Donald J BrownGavin Herbert Eye Institute, University of California Irvine, Irvine, CA, United States.
James V JesterGavin Herbert Eye Institute, University of California Irvine, Irvine, CA, United States. Electronic address: JJester@uci.edu.
University of California, Irvine · USYonsei University · KR

Funding

Age-Related Meibomian Gland DysfunctionR01EY021510 · NEI · UNIVERSITY OF CALIFORNIA-IRVINE · PI James V Jester · 2011 to 2026
$4.8M
NEI NIH HHS R01 EY021510
6 · The paper itself

Abstract

purposeTo evaluate the role of PPARγ in regulating meibocyte differentiation and lipid synthesis in a human meibomian gland epithelial cell line (hMGEC).

methodsHMGEC were exposed to the PPARγ agonist, Rosiglitazone, from 10-50 μM. Cultures were also exposed to specific PPARγ antagonist, T0070907, to block PPARγ receptor signaling. Cells were then stained with Ki-67 and LipidTox to determine the effects on cell cycling and lipid synthesis, respectively. Expression of meibocyte differentiation related proteins, ADFP, PPARγ, ELOVL4, and FABP4, were evaluated by quantitative PCR and western blotting. A human corneal epithelial cell line (hTCEpi) was used as a control.

resultRosiglitazone significantly decreased Ki-67 staining within 2 days in a dose-dependent manner (P = 0.003) and increased lipid accumulation in hMGEC in a dose dependent manner. T0070907 suppressed both lipid droplet synthesis and cell cycle exit. Rosiglitazone significantly upregulated expression of ADFP, PPARγ, ELOVL4, and FABP4 by 9.6, 2.7, 2.6, and 3.3 fold on average (all P < 0.05 except for FABP4, P = 0.057) in hMGEC. T0070907 significantly abrogated rosiglitazone-induced upregulation of these genes when treated prior to rosiglitazone treatment (all P < 0.05). The observed lipogenic differentiation response was not duplicated in hTCEpi after exposure to rosiglitazone.

conclusionRosiglitazone induced cell cycle exit and upregulation of lipogenic gene expression leading to lipid accumulation in hMGEC. These effects were suppressed by PPARγ antagonist indicating that PPARγ signaling specifically directs lipogenesis in hMGEC. These findings suggest that PPARγ plays a critical role in meibocyte differentiation.

Indexed as

Cell DifferentiationCells, CulturedEpithelial CellsHumansLipidsLipogenesisMeibomian GlandsPPAR gammaRosiglitazoneLipidsPPAR gammaRosiglitazoneMeibocyteMeibomian glandMGDPPAR

Identifiers

PMID29990545
PMCPMC6434942
OpenAlexW2739861184

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.